Exploring Biliary Tract Cancer: Top Takeaways From ASCO GI 2025 - Episode 13

Key Takeaways From ASCO GI 2025: Exciting Updates on BTC

April 2, 2025

Shubham Pant, MD, Haley Ellis, MD , Amit Mahipal, MD, Darshil Shah, MD, MPH

Panelists discuss how recent research presentations and data updates at the latest scientific meeting have advanced the understanding and treatment landscape of biliary tract cancer (BTC).

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Guiding Patients Through Advanced BTC Prognosis and Expectations

EP. 2: The Importance of Early Biomarker Testing in Managing Advanced BTC

EP. 3: Biomarker Testing in BTC: Approaches and Practices Across Academic and Community Clinicians

EP. 4: Expert Insights: Challenges With ctDNA Testing in BTC

EP. 5: Landmark Trials in First-Line Treatment Landscape for Advanced BTC: Expert Insights from TOPAZ-1 and KEYNOTE-966 Trials

EP. 6: Applying Data to Clinical Practice: Immunotherapy in the First-Line Treatment Setting in Advanced BTC

EP. 7: Understanding HER2 Testing in BTC: Detection and Clinical Approaches

EP. 8: Expert Perspectives From DESTINY-PanTumor 02 and Real-World Experience with Trastuzumab Deruxtecan in HER2-Positive BTC

EP. 9: New Approvals in HER2-Positive BTC: Zanidatamab - Key Findings from HERIZON-BTC-01 Study

EP. 10: Expert Perspectives in HER2-Positive BTC: Trastuzumab With Pertuzumab or Tucatinib From MyPathway and SGNTUC-019 Trials

EP. 11: Clinical Insights: Incorporating Zanidatamab and Other HER2-Targeted Agents Into the Real-World Practice in Advanced BTC

EP. 12: Future Perspectives and Unmet Needs in HER2-Positive Advanced BTC Treatment

Now Viewing

EP. 13: Key Takeaways From ASCO GI 2025: Exciting Updates on BTC

Video content above is prompted by the following:

At ASCO GI 2025, a number of abstracts and new data were presented. Will each of you share any key takeaways or additional data updates that you found particularly exciting surrounding BTC?